The USA’s Institute for Clinical and Economic Review (ICER) has released an Evidence Report assessing the comparative clinical effectiveness and value of Hemlibra (emicizumab).
The report found that emicizumab, from Swiss pharma giant Roche’s (ROG: SIX) subsidiary Genentech, offers important improvements in outcomes for people with hemophilia A and inhibitors to Factor VIII, while lowering costs associated with the treatment of this condition.
Emicizumab was approved by the US Food and Drug Administration in November of 2017 for prophylaxis (prevention of bleeding) in adults and children who have hemophilia A with coagulation factor VIII inhibitors. Factor VIII is the clotting protein that is deficient in those with hemophilia A, and inhibitors interfere with the factor replacement therapy that would typically be used to treat the condition.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze